retatrutide phase 2 trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people LLY's Retatrutide Nears 2027 Filing

Association of PCSK1 Rs6234 with Obesity and Related Traits in a Chinese Han Population. PloS One, vol

[16] GLP-1 endogenous in humans [16] glucagon endogenous in humans [16] oxyntomodulin amycretin/ zenagamtide UBT251 exendin-4 [16] [17] exenatide lixisenatide [16] albiglutide beinaglutide dulaglutide efpeglenatide langlenatide liraglutide [16] polyethylene glycol/PEG- loxenatide semaglutide taspoglutide ecnoglutide utreglutide glepaglutide apraglutide maridebart cafraglutide tirzepatide pegapamodutide mazdutide survodutide bamadutide pemvidutide cotadutide retatrutide Lithium chloride Cinchonine grutalumab dapiglutide DA1726 GX-G6 GZR18 HRS9531/ KAI-9531/ Ribupatide PB718 RAY1225 VCT220 VK2735 BLX7006 supaglutide/ efsubaglutide ASC30 HRS7535 Danuglipron Aleniglipron Lotiglipron Orforglipron (non peptide partial agonist) [18] Conveglipron Elecoglipron/ AZD 5004/ ECC 5004 CT-996 CT-388/ Enicepatide CT-868 HEC88473 HS-10535 UBT251 efinopegdutide efocipegtrutide Berobenatide NNC9204-1706 TG103 YP05002/YP-05002 Positive Negative Clinical significance [edit] GLP-1 receptor agonists are a class of medications that mimic the actions of the endogenous incretin hormone GLP-1, and are used in type 2 diabetes and obesity

Researchers believe retatrutide may help increase fat metabolism because of its glucagon receptor activity

Accompanied by neurologic symptoms such as leg weakness, numbness, bowel or bladder dysfunction, or saddle anesthesiathese are red flags for cauda equina syndrome or severe nerve compression requiring emergency evaluation

Data from 809 hospitals show a 32% decrease in bariatric surgery volumes from 2022 to 2024

What is Obesity: Everything You Need to Know Obesity has become a significant public health concern in the UK, impacting millions of adults and children, with countless people struggling